214 related articles for article (PubMed ID: 34210752)
21. Inhibition of the Histone Methyltransferase EZH2 Enhances Protumor Monocyte Recruitment in Human Mesothelioma Spheroids.
Mola S; Pinton G; Erreni M; Corazzari M; De Andrea M; Grolla AA; Martini V; Moro L; Porta C
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922336
[TBL] [Abstract][Full Text] [Related]
22. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.
Wu S; Fatkhutdinov N; Fukumoto T; Bitler BG; Park PH; Kossenkov AV; Trizzino M; Tang HY; Zhang L; Gardini A; Speicher DW; Zhang R
Nat Commun; 2018 Oct; 9(1):4116. PubMed ID: 30297712
[TBL] [Abstract][Full Text] [Related]
23. EZH2-mediated Epigenetic Silencing of miR-29/miR-30 targets LOXL4 and contributes to Tumorigenesis, Metastasis, and Immune Microenvironment Remodeling in Breast Cancer.
Yin H; Wang Y; Wu Y; Zhang X; Zhang X; Liu J; Wang T; Fan J; Sun J; Yang A; Zhang R
Theranostics; 2020; 10(19):8494-8512. PubMed ID: 32754259
[TBL] [Abstract][Full Text] [Related]
24. miR-638 promotes melanoma metastasis and protects melanoma cells from apoptosis and autophagy.
Bhattacharya A; Schmitz U; Raatz Y; Schönherr M; Kottek T; Schauer M; Franz S; Saalbach A; Anderegg U; Wolkenhauer O; Schadendorf D; Simon JC; Magin T; Vera J; Kunz M
Oncotarget; 2015 Feb; 6(5):2966-80. PubMed ID: 25650662
[TBL] [Abstract][Full Text] [Related]
25. Dysregulated lipid metabolism blunts the sensitivity of cancer cells to EZH2 inhibitor.
Zhang T; Guo Z; Huo X; Gong Y; Li C; Huang J; Wang Y; Feng H; Ma X; Jiang C; Yin Q; Xue L
EBioMedicine; 2022 Mar; 77():103872. PubMed ID: 35158113
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological inhibition of EZH2 by ZLD1039 suppresses tumor growth and pulmonary metastasis in melanoma cells in vitro and in vivo.
Zhu Y; Zhang L; Song X; Zhang Q; Wang T; Xiao H; Yu L
Biochem Pharmacol; 2023 Apr; 210():115493. PubMed ID: 36898415
[TBL] [Abstract][Full Text] [Related]
27. The Ezh2 polycomb group protein drives an aggressive phenotype in melanoma cancer stem cells and is a target of diet derived sulforaphane.
Fisher ML; Adhikary G; Grun D; Kaetzel DM; Eckert RL
Mol Carcinog; 2016 Dec; 55(12):2024-2036. PubMed ID: 26693692
[TBL] [Abstract][Full Text] [Related]
28. EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.
Julia E; Salles G
Future Oncol; 2021 Jun; 17(17):2127-2140. PubMed ID: 33709777
[TBL] [Abstract][Full Text] [Related]
29. Pharmacology and pharmacokinetics of tazemetostat.
Orleni M; Beumer JH
Cancer Chemother Pharmacol; 2024 May; 93(5):509-517. PubMed ID: 38520556
[TBL] [Abstract][Full Text] [Related]
30. EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression.
Fan T; Jiang S; Chung N; Alikhan A; Ni C; Lee CC; Hornyak TJ
Mol Cancer Res; 2011 Apr; 9(4):418-29. PubMed ID: 21383005
[TBL] [Abstract][Full Text] [Related]
31. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
[TBL] [Abstract][Full Text] [Related]
32. Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAF
Fu H; Cheng L; Sa R; Jin Y; Chen L
J Cell Mol Med; 2020 Mar; 24(6):3336-3345. PubMed ID: 31970877
[TBL] [Abstract][Full Text] [Related]
33. CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer.
Nie L; Wei Y; Zhang F; Hsu YH; Chan LC; Xia W; Ke B; Zhu C; Deng R; Tang J; Yao J; Chu YY; Zhao X; Han Y; Hou J; Huo L; Ko HW; Lin WC; Yamaguchi H; Hsu JM; Yang Y; Pan DN; Hsu JL; Kleer CG; Davidson NE; Hortobagyi GN; Hung MC
Nat Commun; 2019 Nov; 10(1):5114. PubMed ID: 31704972
[TBL] [Abstract][Full Text] [Related]
34. EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma.
Tiffen J; Gallagher SJ; Filipp F; Gunatilake D; Emran AA; Cullinane C; Dutton-Register K; Aoude L; Hayward N; Chatterjee A; Rodger EJ; Eccles MR; Hersey P
J Invest Dermatol; 2020 Dec; 140(12):2442-2454.e5. PubMed ID: 32360600
[TBL] [Abstract][Full Text] [Related]
35. No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3.
Wiese M; Schill F; Sturm D; Pfister S; Hulleman E; Johnsen SA; Kramm CM
Klin Padiatr; 2016 Apr; 228(3):113-7. PubMed ID: 27135271
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic Silencing of miRNA-34a in Human Cholangiocarcinoma via EZH2 and DNA Methylation: Impact on Regulation of Notch Pathway.
Kwon H; Song K; Han C; Zhang J; Lu L; Chen W; Wu T
Am J Pathol; 2017 Oct; 187(10):2288-2299. PubMed ID: 28923203
[TBL] [Abstract][Full Text] [Related]
37. Expression of AP-2alpha, c-kit, and cleaved caspase-6 and -3 in naevi and malignant melanomas of the skin. A possible role for caspases in melanoma progression?
Woenckhaus C; Giebel J; Failing K; Fenic I; Dittberner T; Poetsch M
J Pathol; 2003 Oct; 201(2):278-87. PubMed ID: 14517845
[TBL] [Abstract][Full Text] [Related]
38. NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2.
De Donatis GM; Le Pape E; Pierron A; Cheli Y; Hofman V; Hofman P; Allegra M; Zahaf K; Bahadoran P; Rocchi S; Bertolotto C; Ballotti R; Passeron T
Oncogene; 2016 May; 35(21):2735-45. PubMed ID: 26364600
[TBL] [Abstract][Full Text] [Related]
39. Genomic deregulation of the E2F/Rb pathway leads to activation of the oncogene EZH2 in small cell lung cancer.
Coe BP; Thu KL; Aviel-Ronen S; Vucic EA; Gazdar AF; Lam S; Tsao MS; Lam WL
PLoS One; 2013; 8(8):e71670. PubMed ID: 23967231
[TBL] [Abstract][Full Text] [Related]
40. EZH2-Mediated Downregulation of the Tumor Suppressor DAB2IP Maintains Ovarian Cancer Stem Cells.
Zong X; Wang W; Ozes A; Fang F; Sandusky GE; Nephew KP
Cancer Res; 2020 Oct; 80(20):4371-4385. PubMed ID: 32816909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]